EpiCure

The project EpiCure is currently undertaking the transition from basic research at LMU Munich to industry and will be incorporated soon. At EpiCure, we are dedicated to developing groundbreaking cancer therapeutics. Our flagship product, Carbacitabin, is poised to revolutionize leukemia treatment and is already internationally patented. We aim to expand Carbacitabin's indications while actively exploring additional nucleic acid-based therapeutics. Our mission is to provide cancer patients, especially those with leukemia, with a low side-effect yet highly effective treatment. Join us on our journey to reshape the landscape of cancer therapy. #EpiCure #CancerTreatment #Innovation #leukemia